Vivimed Labs Limited
Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.
What Vivimed files
- Others28
- Important21
- Updates11
- Board Meeting6
- Results3
Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process
Vivimed's share transfer agent reported no re-lodgement requests for physical shares in June. Zero requests were received, processed, approved, or rejected, indicating no operational activity in physical share transfers.
Vivimed has postponed its board meeting, originally for approval of the financial results for the quarter and year. A revised date for the board meeting will be announced in due course.
Vivimed Labs faced a ₹2.95 Lakh fine from stock exchanges for a 25-day delay in filing its December quarter financial results, caused by the CFO's resignation. The annual secretarial compliance report otherwise confirms strong adherence to governance.
Vivimed Labs confirms it is not classified as a 'large corporate entity' under current regulatory guidelines. This status update provides clarity on its compliance position for investors.